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Summary  The  widespread  use  of  combination  antiretroviral  therapy  (cART)  among  people  liv-
ing with  HIV  in  developed  countries  has  lead  to  signiﬁcantly  improved  life  expectancy.  However,
extensive use  of  the  effective  cART  coincides  with  increasing  reports  of  coronary  heart  disease
(CHD) among  people  living  with  HIV,  and  CHD  has  become  a  major  cause  of  death.  CHD  results
from a  complex  and  multifactorial  atherosclerotic  process  involving  the  over-representation
of traditional  cardiovascular  risk  factors,  particularly  smoking,  uncontrolled  viral  replication,
chronic  inﬂammation,  immune  activation,  and  exposure  to  antiretroviral  drugs.  Consequently
careful selection  of  antiretroviral  drugs,  cardiovascular  risk  reduction,  and  lifestyle  modiﬁca-
tions are  needed.  In  individuals  living  with  HIV,  cardiovascular  risk  assessment  is  becoming  an
important element  of  care.
© 2015  Published  by  Elsevier  Masson  SAS.
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Résumé  Dans  les  pays  industrialisés,  l’utilisation  généralisée  des  combinaisons  d’antirétrov-
iraux (cART)  chez  les  personnes  vivant  avec  le  VIH  a  conduit  à  une  amélioration  signiﬁcative  de
l’espérance  de  vie.  Cependant,  l’ample  utilisation  des  cART  coïncide  avec  une  augmentation
des cas  de  maladie  coronaire  rapportés  chez  les  personnes  vivant  avec  le  VIH  et  la  maladie
coronaire  est  devenue  une  cause  majeure  de  décès.  La  maladie  coronaire  est  la  résultante
d’un processus  d’athérosclérose  complexe  et  multifactoriel  impliquant  la  sur-représentation
des facteurs  de  risque  cardiovasculaires  traditionnels,  notamment  le  tabagisme,  la  réplica-
tion virale  non  contrôlée,  l’inﬂammation  chronique,  l’activation  immunitaire  et  l’exposition
aux traitements  antirétroviraux.  Par  conséquent,  une  sélection  rigoureuse  des  traitements
antirétroviraux,  une  réduction  des  risques  cardiovasculaires  et  des  modiﬁcations  de  style  de  vie
sont nécessaires.  Chez  les  personnes  vivant  avec  le  VIH,  l’évaluation  du  risque  cardiovasculaire
devient  un  élément  important  de  la  prise  en  charge.
© 2015  Publié  par  Elsevier  Masson  SAS.
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[Cardiovascular  diseases  (CVDs)  are  the  leading  cause  of
death  worldwide  [1].  In  individuals  infected  by  the  human
immunodeﬁciency  virus  (HIV),  CVDs  account  for  an  increas-
ingly  large  proportion  of  deaths,  especially  in  those  treated
with  effective  combination  antiretroviral  therapy  (cART)
[2,3].  This  article  aims  to  assess  the  current  epidemiolog-
ical  evidence  linking  HIV  infection  to  coronary  heart  disease
(CHD),  and  the  speciﬁc  clinical  factors  that  may  exist  at  clin-
ical  presentation  in  HIV-infected  individuals  compared  with
uninfected  individuals.
Overall risk of coronary heart disease
The  natural  history  of  HIV  disease  has  changed  in
countries  where  people  living  with  HIV  have  access  to
cART.  The  individuals  receiving  combination  ART  regimens
experience  fewer  opportunistic  AIDS-related  diseases  and
live  longer  than  those  without  access  to  cART.  These
same  individuals  however  develop  long-term  age-related
complications.  Cardiac  complications  have  shifted  from
myocardial  and  pericardial  diseases  linked  to  immunosup-
pression  to  atherosclerotic  diseases  including  myocardial
infarction  and  peripheral  and  cerebrovascular  diseases
[4—6].  Several  large  observational  cohorts  and  cohort  col-
laborations  including  persons  living  with  HIV  have  examined
their  speciﬁc  causes  of  mortality.  The  Antiretroviral  Ther-
apy  Cohort  Collaboration,  including  patients  from  Europe
and  North  America,  reported  that  cardiovascular  deaths
accounted  for  6.5%  of  total  deaths  [2].  Cardiovascular
deaths  accounted  for  15%  of  total  deaths  in  the  US  outpa-
tient  HOPS  study  [3],  for  10%  in  the  French  ‘‘Mortalité  2010’’
survey  [7],  and  for  6%  in  the  Swiss  HIV  Cohort  Study  [8].
Reports  from  as  early  as  2007  describe  an  increased  risk
of  myocardial  infarction  in  HIV-infected  versus  uninfected
populations  [9—12].  Using  data  from  the  US  health  care
system-based  cohort  study,  in  2007,  Triant  et  al.  put  forward
an  adjusted  risk  ratio  of  1.75  (95%  conﬁdence  interval  [CI]
1.51—2.02)  for  myocardial  infarction  in  HIV-infected  versus
uninfected  groups  [9].  In  2011,  using  information  collected
by  the  Régie  de  l’Assurance  Maladie  du  Québec  (RANQ),
Durand  et  al.  estimated  the  adjusted  incidence  ratio  for
myocardial  infarction  in  HIV-infected  individuals  compared
h
u
to  uninfected  individuals  was  2.11  (95%  CI  1.69—2.63)  [10].
urthermore,  in  2013,  Freiberg  et  al.  found  HIV-positive  vet-
rans  in  the  Veterans  Aging  Cohort  Study  Virtual  Cohort
VACS-VC)  had  an  increased  risk  of  incident  myocardial
nfarction  compared  with  uninfected  veterans,  with  an
djusted  hazard  ratio  (HR)  of  1.48  (95%  CI  1.27—1.72)  [11].
Based  on  information  drawn  from  the  French  Hospital
atabase  on  HIV  (FHDH),  in  2010,  Lang  et  al.  found  the
ex-  and  age-standardized  morbidity  ratio  of  people  living
ith  HIV  compared  to  the  general  population  was  estimated
s  1.5  (95%  CI  1.3—1.7)  overall  [12].  As  in  several  cohorts,
he  Lang  et  al.’s  study  showed  that  people  living  with  HIV
xperience  myocardial  infarction  earlier,  at  around  age  50
9,12—15],  while  in  the  uninfected  population  myocardial
nfarction  commonly  occurs  after  60  years  of  age.  Such  ﬁnd-
ngs  suggest  a potential  acceleration  of  atherosclerosis  in
IV-infected  populations.  However,  before  stating  that  there
s  a  premature  aging  process,  it  is  crucial  to  note  that  the  age
istribution  of  HIV-infected  and  uninfected  populations  dif-
er.  Consequently,  it  is  important  to  take  this  variability  into
ccount  when  making  comparisons.  Recently,  Petoumenos
t  al.  observed  only  limited  evidence  of  accelerating  risk  of
VD  with  age  in  the  D:A:D  cohort  compared  with  the  gen-
ral  population  [16]. In  any  case,  if  people  living  with  HIV
ay  experience  accelerated  atherosclerosis  development  it
s  possibly  the  result  of  their  higher  exposure  to  cardiovas-
ular  risk  factors  including  tobacco  and  illicit  drugs,  higher
revalence  of  co-morbidities,  antiretroviral  therapy,  and/or
he  result  of  the  HIV  infection  per  se.  This  will  be  discussed
ater  in  the  article.
raditional cardiovascular risk factors and
linical presentation
n  primary  prevention,  people  living  with  HIV  already  have
 higher  calculated  risk  of  CHD  compared  to  the  same-age
eneral  population  [17,18].  They  are  also  at  higher  rate  of
ardiovascular  risk  factors,  such  as  smoking  and  dyslipidemia
17,18].  Furthermore,  HIV-infected  individuals  seem  to  be  at
igher  risk  of  coronary  artery  disease  than  the  general  pop-
lation.  As  demonstrated  in  2004  by  Bergersen  et  al.  [19],
wice  as  many  people  living  with  HIV  taking  highly  active
2A
c
N
i
a
i
y
ﬁ
m
c
r
r
e
s
1
H
a
b
d
l
d
c
w
t
m
r
d
c
i
C
a
a
c
r
e
s
c
t
t
a
M
d
t
h
t
h
e
p
t
g
1
c
c
n
r
t
c
T
2
a
s
o
f
d
c
p
t
i
s
i
t
(
w
m
a
A
i
l
s
t
a
i
d
d
I
O
t
t
T
p
o
t
(
c
f
S
I
c
S
a
m
t
w
p
s
F
s
d
i
r08  
RT  had  an  estimated  10-year  CHD  Framingham  risk  >  20%  as
ompared  to  control  participants.
From  a  cohort  of  309  individuals  living  with  HIV,  in  2004
eumann  et  al.  [20]  found  the  risk  of  cardiovascular  events
s  related  to  the  age  of  HIV-infected  individuals.  The  over-
ll  10-year  probability  for  cardiovascular  events  was  higher
n  the  oldest  group  (>  50  years;  median  20.5%)  than  in  the
oungest  group  (18—30  years;  median  1.9%;  P  <  0.01).  These
ndings  suggest  that  an  increased  duration  of  life  due  to
ore  effective  ART  has  a  signiﬁcant  impact  on  the  rate  of
ardiovascular  events  in  HIV-infected  populations.
Hadigan  et  al.  [21]  in  2003  estimated  the  10-year  CHD
isk  among  91  men  and  women  living  with  HIV  who  expe-
ienced  fat  redistribution,  and  compared  it  with  the  risk
stimated  for  273  age-,  sex-,  and  body  mass  index-matched
ubjects  enrolled  in  the  Framingham  Offspring  Study.  The
0-year  CHD  risk  estimate  was  signiﬁcantly  elevated  among
IV-infected  individuals  with  fat  redistribution,  particularly
mong  men.  However,  when  matched  with  control  subjects
y  waist-to-hip  ratio,  the  10-year  CHD  risk  estimate  did  not
iffer  signiﬁcantly  between  groups.  In  this  study,  individuals
iving  with  HIV  presenting  no  evidence  of  fat  redistribution
id  not  demonstrate  elevated  10-year  CHD  risk  estimate
ompared  with  control  subjects.  Also,  the  CHD  risk  estimate
as  greatest  in  HIV-infected  individuals  with  primary  lipoa-
rophy  as  compared  to  those  with  either  lipohypertrophy  or
ixed  fat  redistribution.  A  severe  subcutaneous  fat  loss  is
ecognized  as  predisposing  individuals  to  insulin  resistance,
iabetes,  and  dyslipidemia.
More  recently,  in  2007,  Knobel  et  al.  [22]  described  the
ardiovascular  risk  factors  in  a  cohort  of  760  persons  liv-
ng  with  HIV.  They  compared  the  Framingham,  Prospective
ardiovascular  Munster  [PROCAM]  and  SCORE  equations.  The
uthors  observed  that  the  Framingham  equation  categorized
 higher  proportion  of  HIV-infected  males  with  moderate
ardiovascular  risk  and  a  lower  proportion  of  those  with  low
isk  (P  <  0.0001)  compared  with  PROCAM  and  SCORE.  How-
ver,  regardless  of  the  equation  used,  the  Knobel  et  al.  study
howed  a  high  prevalence  of  HIV-infected  individuals  at  low
ardiovascular  risk  (between  76.6%  and  90.1%).
In  2003,  the  French  APROCO  study  group  [18]  compared
he  distribution  of  cardiovascular  risk  factors  in  227  pro-
ease  inhibitors  treated  HIV-infected  individuals  who  were
ged  35—44  years  with  527  HIV-uninfected  men  from  the
ultinational  MONItoring  of  trends  and  determinants  in  CAr-
iovascular  disease  (MONICA)  project.  Saves  et  al.  found
hat  HIV-1  infected  individuals  had  a  lower  prevalence  of
ypertension,  a  lower  mean  high-density  lipoprotein  choles-
erol  concentration,  a  higher  prevalence  of  smoking,  a
igher  mean  waist-to-hip  ratio,  and  a  higher  mean  triglyc-
ride  concentration.  They  found  no  difference  for  total
lasma  or  low-density  cholesterol  concentrations,  or  for
he  prevalence  of  diabetes.  The  predicted  risk  of  CHD  was
reater  among  HIV-1  infected  men  (RR  1.20)  and  women  (RR
.59;  P  <  10—6  for  both)  compared  with  in  the  uninfected
ohort.
In  the  Swiss  HIV  Cohort  Study  [23],  where  8033  individuals
ompleted  at  least  one  cardiovascular  risk  factor  question-
aire,  Glass  et  al.  found,  in  2006,  that  the  most  common
isk  factors  were  smoking  (57.0%),  low  high-density  lipopro-
ein  cholesterol  concentration  (37.2%),  high  triglycerides
oncentration  (35.7%),  and  high  blood  pressure  (26.1%).
o
r
i
oS.  Lang  et  al.
hey  reported  the  10-year  CHD  risk  as  being  high  (>  20%)  in
.7%  of  all  participants  and  moderate  (10—20%)  in  13.8%  of
ll  participants.  Over  6  years,  they  found  the  percentage  of
mokers  decreased  from  61.4%  to  47.6%  and  the  percentage
f  individuals  with  total  cholesterol  >  6.2  mmol/L  decreased
rom  21.1%  to  12.3%.  They  reported  that  prevalence  of  car-
iovascular  risk  factors  and  CHD  was  higher  in  participants
urrently  on  ART  than  in  either  pre-treated  or  ART-naive
ersons.
Among  individuals  living  with  HIV,  the  clinical  presenta-
ion  of  CHD  is  similar  to  that  in  the  general  population,  and
ncludes  silent  ischemia,  stable  angina,  and  acute  coronary
yndrome  (ACS).  ACS  is  the  main  CHD  clinical  presentation
n  this  young  population,  particularly  ST-segment  eleva-
ion  myocardial  infarction  (Table  1).  In  six  studies  [24—29],
Table  1) comparing  persons  hospitalized  for  ACS  with  or
ithout  HIV  infection,  results  showed  that  the  most  com-
on  proﬁle  of  a  person  living  with  HIV  presenting  an  ACS  is
 young  man  (90%  male,  ≤  50  years),  most  often  treated  with
RT  (varying  from  53%  to  96%)  and  mainly  taking  protease
nhibitors  (>  59%).  When  focusing  on  traditional  cardiovascu-
ar  risk  factors,  HIV-infected  individuals  are  more  frequently
mokers  and  cocaine  users,  but  are  less  likely  to  have  hyper-
ension  or  diabetes  mellitus  (Table  1).  In studies  looking
bout  cause  of  sudden  cardiac  death  (SCD)  in  HIV-infected
ndividuals  some  discrepancy  exists  due  to  differences  in
eﬁnitions  used.  For  example,  in  2012  Tseng  et  al.  [30]
eﬁned  SCD  as  deaths  meeting  two  criteria:  the  primary
CD-10  code  for  all  cardiac  causes  and  the  World  Health
rganization  stipulation  of  death  within  24  hours  of  symp-
oms.  However,  the  same  year,  Worm  et  al.  [31]  limited
he  time  component  to  death  within  6  hours.  Subsequently,
seng  et  al.  [30]  found  mean  SCD  rate  was  2.6  per  1000
erson-years  (95%CI  1.8—3.8)  with  SCDs  accounting  for  86%
f  all  cardiac  deaths  while  Worm  et  al.  [31]  calculated
he  sudden  death  rate  as  0.33  cases  per  1000  person-years
95%CI  0.26—0.41).  In  light  of  such  issues  around  traditional
ardiovascular  risk  factors  and  their  clinical  presentation,
urther  studies  investigating  the  underlying  mechanisms  of
CD  and  providing  insight  into  causes  of  death  are  necessary.
mpact of antiretroviral therapy on
oronary heart disease
ome  antiretroviral  drugs,  particularly  protease  inhibitors,
ppear  to  be  involved  in  the  increased  rate  of  CHD,  including
yocardial  infarction.  The  ﬁrst  cases  of  myocardial  infarc-
ion  in  HIV-infected  individuals  receiving  protease  inhibitors
ere  reported  in  the  late  1990s  [32—35].  All  the  patients
resented  in  these  cases  were  aged  ≤  60  years,  were  heavy
mokers  and/or  had  an  abnormal  cholesterol  concentration.
ollowing  these  initial  descriptions  of  myocardial  infarction,
everal  epidemiological  studies  [10,15,36—47]  were  con-
ucted  to  assess  whether  ART  could  be  implicated  as  a  factor
n  the  increased  risk  of  CVD  (Table  2).  Some  of  these  studies
eport  no  increased  risk  of  CVD  linked  to  ART  exposure,  while
ther  set  forward  evidence  of  an  association  between  the
isk  of  CVD  and  exposure  to  ART  (Table  2).  Such  disparities
n  the  studies’  ﬁndings  may  be  related  to  the  fact  that  each
f  these  studies  differing  in  design  and  sample  size,  have
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Table  1 Summary  of  studies  comparing  cardiovascular  risk  factors  in  HIV-infected  and  uninfected  individuals  with  ACS.
First  Author
Study  Period
Study  Design
HIV+  vs.  HIV− Risk  factors  HIV+  vs.  HIV−, %
n  Type  of  ACS,  % Age, y
Men,  %
Tobacco
use
Cocaine  use Premature
familial  CHD
Hypertension  Diabetes
mellitus
Dyslipidemia
Matetzky  et  al.  [24]
1998—2000
Prospective
case-control
24 vs.  48 STEMI  58  vs.  58
NSTEMI  42  vs.  42
UA  0
47 ±  9  vs.
48  ±  7
88  vs.  88
58 vs.  48 0  50  vs.  44 29  vs.  44 12  vs.  19 58  vs.  56
Hsue  et  al.  [25]
1993—2003
Database
68 vs.  68 STEMI  29  vs.  35
NSTEMI  25  vs.  37
UA  46  vs.  28*
50  ±  8  vs.
61  ±  11
90  vs.  62*
46  vs.  28* NA  24  vs.  16 36  vs.  41 9  vs.  28 17  vs.  28*
Boccara  et  al.  [26]
2003—2006
Prospective
case-control
103  vs.  195 STEMI  49  vs.  56
NSTEMI  20  vs.  21
UA  31  vs.  23
48  ±  9  vs.
50  ±  9
93  vs.  94
59 vs.  64 5  vs.  2 20  vs.  27 19  vs.  24 9  vs.  12 45  vs.  46
Perelló  et  al.  [27]
2006—2009
Prospective  cohort
44  vs.  583  STEMI  59  vs.  24*
NSTEMI  23  vs.  38*
UA  18  vs.  38*
47  ±  11  vs.
72 ±  21
92  vs.  67*
59  vs.  20* 11  vs.  0.3* 21  vs.  5* 18  vs.  65* 16  vs.  28  36  vs.  49
Pearce  et  al.  [28]
1997—2006
Database
5984  vs.
2,501,904
STEMI  50  vs.  56*
NSTEMI  50  vs.  44*
UA  0
48 ±  0.3  vs.
54 ±  0.02
85  vs.  72*
25  vs.  30  NA  NA  46  vs.  51* 20  vs.  28* 25  vs.  42*
Lorgis  et  al.  [28]
2005—2009
Retrospective
case-control
608  vs.
1216
STEMI  91  vs.  84*
NSTEMI  9  vs.  16*
UA  0
50 ±  10  vs.
68 ±  15*
89  vs.  66*
30  vs.  30 NA  NA  17  vs.  22* 9  vs.  11 31  vs.  29
Adapted from Boccara et al. [56].
ACS: acute coronary syndrome; CHD: coronary heart disease; HIV: human immunodeﬁciency virus; NA: not available; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI:
ST-segment elevation myocardial infarction; UA: unstable angina.
* P < 0.05.
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Table  2  Risk  of  cardiovascular  diseases  among  HIV-infected  individuals  treated  with  cART.
Study
Study  period
Study  design  Events
studied
n  (PY)  Coronary
events,  n
ART-exposed
subjects,  n
(PY)
Duration  of  follow-up
with  ART
Results
Jütte  et  al.  [36]
1990—1998
Database  on
medical  records
No  validation  of
cases
MI  1324  (1911)  8  373  (469)  10  months  (median)  Incidence:  2.1/1000  PY  in
non-PI-treated  patients
vs.  10.6/1000  PY  in
PI-treated  patients
Rickerts  et  al.  [37]
1983—1998
Database  on
medical  records
Validation  of  cases
MI  4993
(16,478)
29  1572  NA  OR  2.61  (95%  CI
1.19—5.66)
ART  vs.  no  ART
David  et  al.  [38]
1999—2000
Database  on
medical  records
Case-control
analysis
No  validation  of
cases
Ischemic
CVD
48  16  34  27  months  for  cases
(median);  14  months
for  controls  (median)
PIs  not  directly  associated
with  greater  risk  of
ischemic  CVD
Holmberg  et  al.  [39]
1993—2002
Database  on
medical  records
Validation  of  cases
MI  5672
(17,712)
21  3247  49  months  (mean)  Higher  risk  for  PIs  vs.
non-PIs:  HR  6.5  (95%  CI
0.9—47.8)
Bozzette  et  al.  [40]
1993—2001
Database  on
administrative
data
No  validation  of
cases
CCVE  36,766
(121,935)
1207  15,296
(26,957)
16  months  (median)  HR  1.23  (95%  CI
0.78—1.93)
24  months  of  PI  exposure
vs.  no  PIs
Klein  et  al.  [41]
1996—2002
Database  on
administrative
data
No  validation  of
cases
MI  4408
(18,792)
65  2860
(10,686)
47  months  (median)  4.0/1000  PY  for  no  PIs  vs.
3.9/1000  PY  with  PIs
Friis-Moller  et  al.  [15]
1999—2002
Speciﬁcally
designed  cohort
Validation  of  cases
MI  23,468
(36,199)
126  17,484  22  months  (median)  RR  1.26  (95%  CI
1.12—1.41)  PY  of  cART
exposure
Mary-Krause  et  al.  [42]
1996—1999
Database  on
medical  records
Validation  of  cases
MI  34,976  men
(88,029)
60  21,906
(39,023)
34  months  (median)  Higher  risk  for  ≥  30
vs.  <  18  months  of  PI
exposure
SMR  3.6  (95%  CI  1.8—6.2)
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Study
Study  period
Study  design Events
studied
n  (PY) Coronary
events,  n
ART-exposed
subjects,  n
(PY)
Duration  of  follow-up
with  ART
Results
d’Arminio  et  al.  [43]
1999—2002
Speciﬁcally
designed  cohort
Validation  of  cases
CCVE  36,145  CCVE  207;  MI
126
NA NA  RR  1.26  (95%  CI
1.14—1.38)  PY  of  cART
exposure
Friis-Moller  et  al.  [44]
1999—2005
Speciﬁcally
designed  cohort
Validation  of  cases
MI  23,437
(94,469)
345  150,758  83  months  (median) RR  1.16  (95%  CI
1.09—1.23)  PY  of  cART
exposure
RR  1.16  (95%  CI
1.10—1.23)  PY  of  PI
exposure
RR  1.05  (95%  CI
0.98—1.13)  PY  of  NNRTI
exposure
Obel  et  al.  [45]
1995—2004
Database  on
medical  records
No  validation  of
cases
Ischemic
CVD
In  non-cART
period,
9271  vs.
1,272,956;
in  cART
period,
13,593  vs.
1,389,722
Before  cART
initiation  14
vs.  1946;  after
cART  initiation
57  vs.  2817
13,593  vs.
1,389,722
In  non-cART  period,  1.6
vs.  2.13  y;  in  cART
period,  5.2  vs.  5.9  y
After  cART  initiation,  the
increased  risk  became
substantially  higher:  RR
2.12  (95%  CI,  1.62—2.76)
RR  did  not  further
increase  in  the  initial  8
years  of  cART
Worm  et  al.  [46]
1999—2008
Speciﬁcally
designed  cohort
Validation  of  cases
MI  33,308
(178,835)
580  NA  NA  MI  incidence  3.2/1000  PY
(95%  CI  3.0—3.5)
RR  cumulative  exposure  to
IDV  1.12  (95%  CI
1.07—1.18)
RR  cumulative  exposure  to
LPV/RTV  1.13  (95%  CI
1.05—1.21)
RR  recent  exposure  to  ABC
1.70  (95%  CI  1.17—2.47)
RR  recent  exposure  to  DDI
1.41  (95%  CI  1.09—1.82)
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Study
Study  period
Study  design  Events
studied
n  (PY)  Coronary
events,  n
ART-exposed
subjects,  n
(PY)
Duration  of  follow-up
with  ART
Results
Lang  et  al.  [43]
2000—2006
Case-control  study
nested  in  database
MI  74,958
(298,156)
289  MI  vs.  884
controls
94% 79  vs.  84  months  MI  incidence  1.24/1000  PY
OR  cumulative  exposure
to  PIs  (except  SQV)  1.53
(95%  CI  1.21—1.94)  PY
RR  recent  exposure  to  ABC
not  signiﬁcantly  increased
when  taking  into  account
cocaine  and  IV  drug  use:
OR  1.27  (95%  CI
0.60—2.49)
Durand  et  al.  [10]
1985—2007
Case-control  study
nested  in  database
MI  7053
(35,851)
125  MI  vs.
1084  controls
76%  NA  MI  incidence  3.88/1000  PY
OR  any  exposure  to  EFV
1.83  (95%  CI  1.21—2.76)
OR  any  exposure  to  LPV
1.98  (95%  CI  1.21—2.76)
OR  any  exposure  to  RTV
2.29  (95%  CI  1.24—3.16)
OR  any  exposure  to  ABC
1.79  (95%  CI  1.16—2.76)
Adapted from Boccara et al. [56].
ABC: abacavir; ART: antiretroviral therapy; cART: combined antiretroviral therapy; CCVE: cardio- and cerebrovascular events; CI: conﬁdence interval; CVD: cardiovascular disease; DDI:
didanosine; EFV: efavirenz; HR: hazard ratio; IDV: indinavir; IV: intravenous; LVP: lopinavir; MI: myocardial infarction; NA: not available; OR: odds ratio; PI: protease inhibitor; PY:
person-years; RR: relative risk; RTV: ritonavir; SMR: standardized morbidity ratio; SQV: saquinavir; NNRTI: non-nucleoside reverse transcriptase inhibitor.
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used  varying  times  of  exposure  to  protease  inhibitors,  and
that  not  all  of  them  had  an  independent  event  committee.
Exposure to protease inhibitors
Only  two  studies  with  myocardial  infarction  as  primary  end-
point  had  a  sufﬁcient  duration  of  exposure  to  protease
inhibitors  to  possibly  capture  CHD  manifestations  [46,47].
In  the  2010  FHDH  study,  cumulative  exposure  to  any  pro-
tease  inhibitor,  except  for  saquinavir,  was  associated  with
an  increased  risk  of  myocardial  infarction  (odds  ratio  [OR]
1.15,  95%  CI  1.06—1.26,  per  year)  [47].  Also  published  in
2010,  in  the  Data  Collection  on  Adverse  Events  of  Anti-HIV
Drugs  (D:A:D)  study  [46],  cumulative  exposure  to  indinavir
or  lopinavir/ritonavir  was  associated  with  an  increased  risk
of  myocardial  infarction  (relative  rate  per  additional  year
1.12,  95%  CI  1.07—1.18  and  1.13,  1.05—1.21,  respectively).
This  same  study  found  no  association  for  saquinavir  or  nel-
ﬁnavir.  In  a  systematic  review  published  in  2013,  Bavinger
et  al.  demonstrated  signiﬁcant  increased  risks  of  myocar-
dial  infarction  with  cumulative  indinavir  use  (RR  1.11,  95%  CI
1.05—1.17)  and  cumulative  exposure  to  lopinavir  (RR  1.22,
95%  CI  1.01—1.47)  based  on  a  pooled  analysis  of  the  two
aforementioned  studies  [48].
D’Ascenzo  et  al.’s  2012  meta-analysis  of  11  studies  found
an  overall  signiﬁcant  risk  of  2.68  (95%  CI  1.89—3.89)  in  par-
ticipants  with  early  exposure  to  protease  inhibitors  based  on
the  pooled  analysis  of  two  studies  reporting  the  incidence
of  acute  myocardial  infarction  in  participants  exposed  to
protease  inhibitors  [49].  No  studies  investigating  each  pro-
tease  inhibitor  individually  reported  an  association  between
nelﬁnavir  or  saquinavir  and  the  risk  of  myocardial  infarction
[46,47].  Concurrently,  the  2013  Monforte  et  al.’s  study  found
there  was  no  evidence  of  an  association  between  cumulative
exposure  to  atazanavir  and  myocardial  infarction  risk  with  a
RR  per  year  of  0.95  (95%  CI  0.87—1.05)  [50]. At  present,  no
data  are  available  describing  the  risk  of  myocardial  infarc-
tion  associated  with  exposure  to  darunavir,  as  this  drug  has
only  been  available  since  2009.
Exposure to non-nucleoside reverse
transcriptase inhibitors
Neither  the  FHDH  nor  the  D:A:D  study  found  signiﬁcant
associations  between  cumulative  exposure  to  efavirenz  or
nevirapine  and  the  risk  of  myocardial  infarction  [46,47].
Exposure to nucleoside reverse transcriptase
inhibitors
The  pooled  data  from  FHDH  and  D:A:D  studies  in  Bavinger
et  al.’s  systematic  review  demonstrate  that  recent  expo-
sure  to  abacavir  was  associated  with  the  risk  of  myocardial
infarction,  with  a  summary  RR  of  1.91  (95%  CI  1.50—2.42).
This  ﬁnding  suggests  a  harmful  association  between  recent
abacavir  use  and  the  risk  of  myocardial  infarction  [48].  How-
ever,  as  sensitivity  analyses  from  the  FHDH  study  revealed
that  the  results  for  abacavir  were  unstable  the  authors  sub-
sequently  concluded  that  no  causal  relationship  could  be
established  [47].  Regarding  exposure  to  didanosine,  recent
C
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xposure  was  associated  with  an  increased  risk  of  myocar-
ial  infarction  in  the  D:A:D  study  (RR  1.41,  95%  CI  1.09—1.82)
ut  not  in  the  FHDH  study  [46,47].  Using  Fisher’s  method
f  combining  P-values  to  aggregate  the  results  of  the  two
forementioned  studies,  Bavinger  et  al.  found  a  harmful
ssociation  (P  = 0.001)  [48].
xposure to integrase inhibitors
or  the  moment,  to  our  knowledge,  no  studies  have  evalu-
ted  the  impact  of  these  new  agents  because  of  their  recent
vailability.
To  conclude,  as  the  increase  in  life  expectancy  con-
erred  by  combination  ART  far  outweighs  the  associated  risk
f  myocardial  infarction,  the  beneﬁt-risk  ratio  of  receiving
reatment  remains  positive.
ther potential risk factors for coronary
eart  disease
n  the  nested  case-control  study  on  myocardial  infarction
ublished  in  2012,  Lang  et  al.  found  that  HIV  replica-
ion,  a  low  CD4  T-cell  nadir  and  a  high  current  CD8  T-cell
ount  are  associated  with  an  increased  risk  of  myocardial
nfarction  independently  of  cardiovascular  risk  factors  and
ntiretroviral  therapy  [51].  Likewise,  Silverberg  et  al.  have
ublished  that  lower  CD4  T-cell  nadir  seems  to  be  inde-
endently  associated  with  MIs,  as  HIV-infected  individuals
ith  recent  CD4  T-cell  or  CD4  T-cell  nadir  ≥  500  cells/mL
ad  similar  MI  rates  compared  with  uninfected  individuals
52]. In  fact,  the  results  from  the  Strategies  for  Manage-
ent  of  Antiretroviral  Therapy  (SMART)  trial  suggest  that
IV  itself  can  independently  increase  the  risk  of  CHD  [53].
his  randomized  trial  found  that  HIV-infected  individuals
ho  discontinued  ART  had  a  higher  rate  of  cardiovascular
vents  than  HIV-infected  individuals  who  not  discontinued
RT,  suggesting  an  indirect  role  of  HIV  viral  rebound  in  the
therothrombosis  process.  Macrophages  probably  play  a  key
ole  in  HIV-related  atherosclerosis.  It  is  possible  that  HIV
nfection  could  affect  all  steps  of  atherogenesis  [54]  through
nhanced  monocyte  activation,  viremia-induced  interferon-
lpha  production  and  adaptive  T-cell  responses,  altered
everse  transendothelial  migration  of  monocyte-derived
acrophages,  and  defective  cholesterol  efﬂux  by  HIV  infec-
ion  which  could  lead  to  promotion  of  plaque  expansion  and
nstability.  Moreover,  claims  have  been  made  that  inﬂam-
atory  conditions  accelerating  atherogenesis  are  resultant
rom  HIV  induced  alterations  of  HIV-infected  individuals’
mmunological  response  in  addition  to  their  exposure  to
arious  xenoantigens  from  HIV  itself  and  other  viral  and
acterial  infections.  Endothelial  dysfunction  has  also  been
eported  in  HIV  infection  [55]. As  the  current  knowledge
ase  is  limited,  the  impact  of  HIV  itself  and  related  immune
isorders  on  the  coagulation  system  needs  to  be  evaluated
n  the  post-ART  era.onclusions
fter  the  impressive  successes  of  cART  in  drastically
ecreasing  fatal  complications  of  severe  immunodepression,
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[14  
ersons  living  with  HIV  taking  cART  are  now  facing  chal-
enges  such  as  CVD  and  particularly  CHD.  Increased  risk  of
HD  in  HIV-infected  populations  compared  with  uninfected
opulations  is  associated  with  multiple  factors  including
raditional  cardiovascular  risk  factors,  use  of  illicit  drugs,
nd  inﬂammatory  and  immunological  disturbances.  The  new
hallenge  for  physicians  involved  in  HIV  care  is  promoting
ardiovascular  risk  prevention,  especially  reinforcing  smok-
ng  cessation  support,  for  populations  living  with  HIV  who
re  at  risk  of  CHD  in  order  to  reduce  the  number  of  coro-
ary  events.  Assessing  the  risk  of  HIV-infected  individuals
ay  present  its  own  set  of  challenges  as  numerous  factors
ssociated  with  CHD  risk  are  not  taken  into  account  when
alculating  different  risk  equations.  In  this  context,  based  on
urrent  best  knowledge,  CHD  risk  equations  for  HIV-infected
atients  should  be  modiﬁed.
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